2016 will be the year for Arqule. We now have two drug candidates under orphan drug status, one major phase 3 trail fully enrolled, and multiple ind's on tap. Takeover or development doesn't matter...my call is 20 a share before August.
(0)
(0)
Deliver breaking news, insightful commentary, and exclusive reports. Get in touch
benzingaheadline@gmail.com.
Target readers who trust our platform to stay ahead of the curve.
